logo-loader
viewQ BioMed Inc.

Q BioMed boosts leadership team with regulatory expert Geoff Fatzinger

Fatzinger, who brings with him 20 years of experience, will also contribute strategic regulatory insight and guidance for the group's portfolio of earlier stage assets

Q BioMed Inc. -
Q BioMed received FDA approval to manufacture and distribute Strontium89 in November last year

Q BioMed Inc (OTCQB:QBIO) has announced the appointment of Geoff Fatzinger as its head of regulatory affairs to focus on the company's global regulatory approval strategy to commercialize its lead cancer bone pain product - the non-opioid Strontium89.

"We are very happy to have Geoff join the team at Q BioMed. His deep global regulatory expertise and strategic leadership is critical as we reach some important milestones, including our effort to globally commercialize Strontium89," Q BioMed CEO Denis Corin said a statement.

READ: Q BioMed taps veteran biotech strategist Kristin Keller as chief commercial officer

Fatzinger, who brings with him 20 years of experience, will also contribute strategic regulatory insight and guidance for the portfolio of earlier stage assets.

He has a demonstrated record of regulatory and business accomplishments covering the United States, Europe, Middle East and Asia Pacific with in-depth experience in Japan, China, and Korea and has extensive experience in drug and device development, clinical trials, and approvals.

"Q BioMed is taking on projects which are providing medical benefit to those with byproducts of illnesses which often go overlooked or minimised. Medicine is not about the 'flavour of the month'," Fatzinger said. "I look forward to helping achieve these goals and bringing medicines to those who need it."

Q BioMed received FDA approval to manufacture and distribute Strontium89 in November last year.

The company completed an initial commercial production run and shipment in February and has begun distribution of the drug in the US, with distribution to EU and rest of the world expected later in the year.

Contact the author at [email protected]

Quick facts: Q BioMed Inc.

Price: 1.82 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $40.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q BioMed activates its marketing campaign for its cancer bone pain drug

Q BioMed Inc (OTCQB:QBIO) Chief Commercialization Officer Kristin Keller tells Proactive the New York-based biotechnology firm has launched a marketing campaign for its non-opioid cancer bone pain drug Strontium89. Keller says the company has created a product website at Strontium89.com to...

1 week ago

2 min read